Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies

Introduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur. One mechanism of resistance is the occurrence of antidrug antibodies. Obinutuzumab and ofatumumab are humanized and hum...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Maxime Teisseyre, Marco Allinovi, Vincent Audard, Marion Cremoni, Giulia Belvederi, Alexandre Karamé, Matteo Accinno, Julien Duquesne, Vinod Sharma, Céline Fernandez, Kévin Zorzi, Mounir El Maï, Vesna Brglez, Sylvia Benzaken, Vincent L.M. Esnault, Alessandra Vultaggio, Harbir Singh Kohli, Raja Ramachandran, Calogero Lino Cirami, Barbara Seitz-Polski
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-03-01
Serie:	Kidney International Reports
Ämnen:	antidrug antibodies immunomonitoring membranous nephropathy obinutuzumab ofatumumab rituximab
Länkar:	http://www.sciencedirect.com/science/article/pii/S2468024924034132
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!